Cardiologist, Associate Prof. of Internal Medicine, Rio de Janeiro State University. Passion for preventive Cardiology, heart failure, art and classical music
Rio de Janeiro, Brasil
Joined October 2012
- Tweets17.3K
- Following844
- Followers5.5K
- Likes35.5K
👇👇
The LCN webinar series on the Optimal Clinic continues! Learn about practical recommendations for organising, strengthening, and harmonising lipid clinics across different healthcare settings. The series focuses on key elements such as education and training, staffing structures, patient pathways, national registries, and healthcare policy.
The overall aim is to improve the prevention of atherosclerotic cardiovascular disease (ASCVD) and other lipid-related disorders, while also promoting more efficient use of healthcare resources.
But what does this look like in Brazil? Join us for this event, chaired by Prof. @pabeda1 & Dr Fabiana Rached and gain an overview of the local landscape: eas.to/LCNWebOCBra
Honoured to share the joint session of @escardio - World Heart Federation - @sbc_cientifico on coronary artery disease at the World Congress of Cardiology - with distiguished colleagues Sergio Montenegro, Amam Mbakwen, Franz Weidinger, Julie Redfern and Carlos Aguiar
#Cardiology
Now there's only ARTEMIS left ongoing. Not too many reasons to be optimist...🙄
#inflammation #cardiovascular #ziltivekimab #atherosclerosis
👇👇
clinicaltrialsarena.com/news…
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 retweeted
🌎 El Dr. @gonzaeperez conversa con el Dr. @Risantilopezcar sobre su participación junto a 9 representantes de sociedades miembro en el Summit de Dolor Precordial en China y los desafíos cardiovasculares de Latinoamérica: mortalidad prematura, recursos, respuesta ante el infarto y nuevas tecnologías.
▶️ youtu.be/0oZVM4yuc-A?si=_KNf…
@DEIC_SBC @sodocardio1 @Sochicaroficial @pabeda1
👇👇👇
Abrir oportunidades de cooperación es esencial para mejorar indicadores que no nos favorecen cuando analizamos que cerca de 350.000 muertes cardiovasculares anuales en America Latina y el Caribe son prematuras. Estamos trabajando en eso desde la @SIAC_cardio
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 retweeted
🌎 América Latina y el Caribe, protagonistas del Chest Pain Summit de la @worldheartfed en Shanghai y Suzhou. El Dr. Ricardo López Santi, junto a representantes de nueve sociedades miembro de la @SIACardio llevaron la voz de la región a la agenda cardiovascular global.
Nota completa 👇
siacardio.com/una-voz-latino…
An opportune trial: Together with STAREE CVOT to be presented at @escardio congress we may finally have an answer whether patients >75 years without prior CVD will benefit from statins aimed at reducing outcomes. #Cardiology
💊 The 82-year-old on a statin since their 60s. No ASCVD, no symptoms, no evidence either way
SAGA/SITE finally randomised it 🔬
📊 3-yr mortality 7.9% continue vs 7.2% stop
✅ Non-inferior (−0.68%, CI −3.95 to 2.60)
❗ No QoL gain from stopping
Shared decision, not a rule
🔗thelancet.com/journals/lanhl…
Zeus study: Ziltivekimab did not meet its primary endpoint of reducing risk of 3-point MACE in pts with CKD, atherosclerosis and residual inflammatory risk.
#atherosclerosis #Inflammation #Prevention
biopharmadive.com/news/novo-…
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 retweeted
🚨 Obicetrapib gets a positive CHMP opinion 🎉
@EMA_News
👉 A new lipid⤵️ 🔧
Oral once-daily CETP inhibitor:
🟢 LDL-C ↓33% (↓49% + ezetimibe)
🟢 Lp(a), ApoB & non-HDL all ↓
⚠️ No CVOT yet, so lipid-lowering only 'til PREVAIL. A 4th-line option to hit targets?
#CKM #CVRM
🔗ema.europa.eu/en/news/meetin…
With all due respect to supercrack Messi and his team...Spain deserved to win. Agree, @Hragy? Congrats @SantosGallegoMD !
Tonight, we brazilians are all egyptian!
💥💥💥👏👏👏 @AliElzieny @Sarah_Moharem
An interesting infograph of what has been achieved so far by studies with the investigational triple agonist #retatrutide. Day by day, a swarm of good news for pts living w/obesity and its comorbidities! @AmarPut @SABOURETCardio @biljana_parapid @cherskams @Hragy @HanCardiomd
Beginning in 20 minutes! @society_eas 👇👇
Please, listen to the video invitation for the @society_eas /Lipid Clinic Network - Brazil and register for free through the link provided below 👇👇. There will be subtitles in English.
#Atherosclerosis #Obesity #Lipids #Prevention
lnkd.in/dnq2iDi8
Please, listen to the video invitation for the @society_eas /Lipid Clinic Network - Brazil and register for free through the link provided below 👇👇. There will be subtitles in English.
#Atherosclerosis #Obesity #Lipids #Prevention
lnkd.in/dnq2iDi8
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 retweeted
As rates of obesity continue to rise, so does the challenge of managing cardiometabolic disease. What lessons can we learn from Brazil?
Join us on 18 June for an insightful webinar covering emerging trends, the cardiovascular effects of obesity, the connections between adiposity, dyslipidaemia and insulin resistance, and why integrated risk management is more important than ever.
Register here: eas.to/LCNWebConBra
As rates of obesity continue to rise, so does the challenge of managing cardiometabolic disease. What lessons can we learn from Brazil?
Join us on 18 June for an insightful webinar covering emerging trends, the cardiovascular effects of obesity, the connections between adiposity, dyslipidaemia and insulin resistance, and why integrated risk management is more important than ever.
Register here: eas.to/LCNWebConBra
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 retweeted
GUÍA ACC 2026 SÍNDROME CARDIO-RENO-METABÓLICO (CRM)
Puntos claves
🔴Estadificar el sd CRM
🔴Estimar riesgo CV con score PREVENT
🔴Evaluar regularmente factores de riesgo Sd CRM
🔴Tratamiento multidisciplinario
🔴Evaluar y tratar sobrepeso y obesidad
🔴En pac con diabetes⏩utilizar fármacos hipoglucemiantes cardioprotectivos (SGLT2i y GLP-1a)
🔴Utilizar TFG y RAC para estimar disfunción renal
🔴Estimar riesgo Sd CRM en pac con enfermerdad aterosclerótica y/o ins. cardíaca⏩optimizar tratamiento
Vía @JACCJournals
jacc.org/doi/10.1016/j.jacc.…
Sergio Kaiser MD, PhD, FACC, FESC 🇧🇷🇮🇱🇷🇴🇺🇦 retweeted
inews.co.uk/news/why-people-…
Great coverage of Irene’s paper @khurramn1 @SABOURETCardio @DrDerekConnolly @drpablocorral @pabeda1
#EASCongress2026 A new actionable pathway is tested in a phase 1 study by @ProfKausikRay and collaborators. Rivonoplast, a potent inhibitor of NLRP3 inflamassome led to early and sustained reversible sCRP reduction compared to placebo. (Follow next tweet👇👇)
Full publication available at jacc.org/doi/10.1016/j.jacc.…
#Prevention #Inflammation #Cardiovascular #Atherosclerosis @azinkh96 @niharika_reddy9 @drpablocorral @SABOURETCardio @MeralKayikcoglu @LaleTokgozoglu @Drlipid @fotisbarkas @FedericaFogacci